---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-043828"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:50:37.293910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Artiva reports 2024 net loss of $65.4M; cash $185.4M; autoimmune data expected H1 2025

## Summary
- Net loss of $65.4M in 2024 vs net income of $28.7M in 2023; no collaboration revenue vs $32.9M prior year.
- Cash, cash equivalents and investments $185.4M at Dec 31, 2024, expected to fund operations through end of 2026.
- Initial data from AlloNK (AB-101) in autoimmune indications (SLE/LN, RA) expected in H1 2025.
- Appointed Dan Baker to Board and added SVP-level leadership in Regulatory, Clinical Ops, and Biometrics.
- Updated Phase 1/2 NHL trial data for AlloNK + rituximab showing durability to be presented at 2025 medical conference.

## SEC filing metadata
- accession: 0000950170-25-043828
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000095017025043828/0000950170-25-043828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000095017025043828/artv-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-043828
- JSON: https://secwatch.observer/filing/0000950170-25-043828.json
- Plain text: https://secwatch.observer/filing/0000950170-25-043828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.